TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary excretion of copper
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoprotein cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical duration of vecuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apolipoprotein B (ApoB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neurodevelopment at 24 months of corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum glucose (FSG) BIAsp 50/BIAsp 70 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(Glu(0‐24 h)) BIAsp 50/BIAsp 70 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of minor hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of combined cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average change in Oswestry score with treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occlusion rate after 5 years
Endpoint domain: Mortality/survival
Primary endpoint: varicose vein recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VCSS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hematological grade 3/4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: PSA test uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity during medical abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of pain during medical abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional stress related to pain management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Achievement of clinical target HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30-day risk of stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: maximal average dilatory amplitude at the arterial side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Complete protection from vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete protection from both nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shared decision making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall success rate of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sites positive for A. actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: days with depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in repetitive behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain ratings measured using the numerical rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of post-operative hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of retrograde infection
Endpoint domain: Adverse events/effects
Primary endpoint: higher analgesic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less patients reporting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: less patients requiring rescue medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hot flush severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in BMD of the lateral spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in BMD of the anteroposterior spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first MACE
Endpoint domain: Mortality/survival
Primary endpoint: haemoglobin A1c decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h mean blood glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bifidobacterium cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerosol deposition in the nasal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nasal deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deposition in the maxillary sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular fibrillation requiring DC cardioversion
Endpoint domain: Adverse events/effects
Primary endpoint: electrocardiographic changes
Endpoint domain: Adverse events/effects
Primary endpoint: late reactions (post discharge symptoms)
Endpoint domain: Adverse events/effects
Primary endpoint: Excretion of urinary conjugated dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary free dopamine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine: noradrenaline ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: light sport activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of GSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidized glutathione concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity levels of antioxidant enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative rate of urinary infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: High blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular Endothelial Function (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Subjective stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of potassium phosphate administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of postpartum major depression
Endpoint domain: Adverse events/effects
Primary endpoint: Intracranial hemorrhage or early death
Endpoint domain: Mortality/survival
Primary endpoint: Renal hyperaminoaciduria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduced glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glomerular proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: opioid misuse risk
Endpoint domain: Adverse events/effects
Primary endpoint: positive psychological health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hazard ratio in ESUS patients
Endpoint domain: Mortality/survival
Primary endpoint: lymphocyte release of tumor necrosis factor-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lymphocyte release of interferon-γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nickel and chromium concentrations in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants losing 5% or more of initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of subsequent asthma deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drowsiness at home
Endpoint domain: Adverse events/effects
Primary endpoint: Depression score (CES-D ≥ 16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-esteem score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: UCLA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure frequency reduction of 50% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Overall seizure severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: tooth color change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of first episodes of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of all-cause hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of starting the medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peripheral revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Injection frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling of incomplete emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress urinary incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in costs for sick leave
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Decrease of BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-surgery blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hourly consumption of local anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time where intragastric pH was >4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean difference in minimal coronary lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischaemic cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: non-haemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Severe persistent fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement of 3 lines or more in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rate of lightwand intubation
Endpoint domain: Adverse events/effects
Primary endpoint: quality of blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enteral protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tyrosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive FiRST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean average pain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean worst pain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Addiction subscale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary end point
Endpoint domain: Mortality/survival
Primary endpoint: EC(50) for tacrolimus and cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentrations in patients with nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcineurin activity in patients with acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve target QTc prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: activity-specific balance confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lesion miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of pancreatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Broad-spectrum antibiotic prescribing adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off-guideline prescribing for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off-guideline prescribing for acute sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MODS
Endpoint domain: Adverse events/effects
Primary endpoint: PaO₂/FiO₂
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of anesthetic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive side effects
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of proximal advanced neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: subjective scoring scale preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % agalactosyl IgG in patients with active arteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: raised antibody to the purified 38‐kDa protein of M. tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: raised antibody to the 65‐kDa HSP of M. leprae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of SLCs
Endpoint domain: Adverse events/effects
Primary endpoint: Benefit-risk balance of FOLFIRINOX versus gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AA loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Negative nitrogen balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impairment of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Night awakenings caused by asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: altered defaecographic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clarity during the day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clarity at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year rates of MACE
Endpoint domain: Mortality/survival
Primary endpoint: AUC0(‐∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Citrulline peaks in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving > or =5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survived days free of acute renal failure treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Whole-body lean mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip bone mineral density loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in monocyte IL-10 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in inflammatory markers (SAA-LDL, CRP, TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: visual field extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task Disengagement (TD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Activation (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to the first request for an analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM time below 3.9 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CGM time above 10 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contrast flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iodine delivery rate (IDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength at three months follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acid inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage reduction in thrombus weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the release of fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative level of functional VWF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total cell count in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pouch failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Median CGQL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of pouch fistulae
Endpoint domain: Adverse events/effects
Primary endpoint: immunologic response to PPSV23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunologic response to influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alanine aminotransferase improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aspartate aminotransferase improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gammaglutamyl transferase improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for paralytic ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of people with at least one severe hypoglycaemic event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of people with impaired hypoglycaemia awareness
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of screen-positive patients receiving brief advice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of IPV perpetration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: growth in family conflict
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean provocative dose of HS required to cause a 20% drop in FEV(1) (HS-PD(20))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraocular pressure > or = 21 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mild cup-disc abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: percent change for CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: functional fitness components improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypophosphatemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Acid-base balance without additional interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes